Medical therapy for glaucoma: What to add after a prostaglandin analogs?

Current Opinion in Ophthalmology

Volumn 26, Issue 2, 2015, Pages 116-120

  Tanna, Angelo P ^a   Lin, Albert B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alpha adrenergic agonist; Beta adrenergic antagonist; Carbonic anhydrase inhibitor; Glaucoma; Prostaglandin analog

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; BRIMONIDINE PLUS BRINZOLAMIDE; BRIMONIDINE PLUS TIMOLOL; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DORZOLAMIDE PLUS TIMOLOL; PROSTAGLANDIN DERIVATIVE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG COMBINATION;

DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE BURNING; EYE PAIN; FATIGUE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NEUROPROTECTION; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REVIEW; TASTE DISORDER; TRABECULOPLASTY; WEAKNESS; XEROSTOMIA; DRUG COMBINATION; DRUG EFFECTS; OCULAR HYPERTENSION; PATHOPHYSIOLOGY;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARBONIC ANHYDRASE INHIBITORS; DRUG COMBINATIONS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; PROSTAGLANDINS, SYNTHETIC;

EID: 84926209617     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0000000000000134     Document Type: Review

References (28)

1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:701-713.
2. Lichter PR, Musch DC, Gillespie BW, et al. CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108:1943-1953.
3. Alvarado JA, Iguchi R, Martinez J, et al. Similar effects of selective laser trabeculoplasty and prostaglandin analogs on the permeability of cultured Schlemm canal cells. Am J Ophthalmol 2010; 150:254-264.
4. Singh D, Coote MA, O'Hare F, et al. Topical prostaglandin analogues do not affect selective laser trabeculoplasty outcomes. Eye 2009; 23:2194-2199.
5. Kara N, Altan C, Satana B, et al. Comparison of selective laser trabeculoplasty success in patients treated with either prostaglandin or timolol/dorzolamide fixed combination. J Ocul Pharmacol Ther 2011; 27:339-342.
6. Lee AC, Mosaed S, Weinreb RN, et al. Effect of laser trabeculoplasty on nocturnal intraocular pressure in medically treated glaucoma patients. Ophthalmology 2007; 114:666-670.
7. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997; 115:847-852.
8. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 1995; 113:1009-1016.
9. Higginbotham EJ, Olander KW, Kim EE, et al. United States Fixed-Combination Study Group. Fixed combination of latanoprost and timolol vs. individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol 2010; 128:165-172.
10. Tanna AP, Rademaker AW, Stewart WC, Feldman RM. Meta-analysis of the efficacy and safety of (2-adrenergic agonists, (-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. Arch Ophthalmol 2010; 128:825-833.
11. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003; 12:393-398.
12. Shedden A, Laurence J, Tipping R. Timoptic-XE 0.5% Study Group. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Clin Ther 2001; 23:440-450.
13. Toris CB, Zhan GL, Zhao J, et al. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol 2001; 131:722-728.
14. Jampel HD, Chon BH, Stamper R, et al. Effectiveness of intraocular pressure-lowering medication determined by washout. J Am Med Assoc Ophthalmol 2014; 132:390-395.
15. Brinzolamide/brominidine (Simbrinza) for glaucoma. Med Lett Drugs Therapeut 2013; 55:57-58.
16. Liu JH, Zhang X, Kripke DF, Weinreb RN. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci 2003; 44:1586-1590.
17. Gulati V, Fan S, Zhao M, et al. Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy. Arch Ophthalmol 2012; 130:677-684.
18. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 2004; 138:389-395.
19. Liu JH, Medeiros FA, Slight JR, Weinreb RN. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology 2010; 117:2075-2079.
20. Liu JH, Medeiros FA, Slight JR, Weinreb RN. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology 2009; 116:449-454.
21. Nau CB, Malihi M, McLaren JW, et al. Circadian variation of aqueous humor dynamics in older healthy adults. Invest Ophthalmol Vis Sci 2013; 54:7623-7629.
22. Reiss GR, Lee DA, Topper JE, Brubaker RF. Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci 1984; 25:776-778.
23. Jonas JB, Nangia V, Wang N, et al. Trans-lamina cribrosa pressure difference and open-angle glaucoma. The Central India Eye and Medical Study. PLoS One 2013; 8:e82284.
24. Saylor M, McLoon LK, Harrison AR, et al. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol 2009; 127:402-406.
25. Krupin T, Liebmann JM, Greenfield DS, et al. Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011; 151:671-681.
26. Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eye drops and nocturnal arterial hypotension. Am J Ophthalmol 1999; 128:301-309.
27. Collaborative Normal-Tension Glaucoma Study Group The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126:498-505.
28. De Moraes CG, Liebmann JM, Greenfield DS, et al. Low-pressure Glaucoma Treatment Study Group. Risk factors for visual field progression in the low-pressure glaucoma treatment study. Am J Ophthalmol 2012; 154:702-711.